Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2‐Low Breast Cancer With Cancer‐Related Microangiopathic Hemolytic Anemia: A Case Report

Authors:

Abstract
The diagnosis of cancer‐related microangiopathic hemolytic anemia (CR‐MAHA) in patients with breast cancer is often delayed, and this condition is associated with high mortality. A 71‐year‐old female with CR‐MAHA secondary to bone marrow metastasis received trastuzumab deruxtecan (T‐DXd) after first‐line chemotherapy failure and achieved partial hematological remission. Treatment was discontinued because of interstitial lung disease (ILD). Early antitumor therapy is crucial; antibody‐drug conjugates such as T‐DXd offer promise, but vigilance for adverse effects is needed.

This publication has 12 references indexed in Scilit: